Efficacy and safety of rituximab treatment in children with primary glomerulonephritis

Journal of Nephrology

Volumn 25, Issue 6, 2012, Pages 1060-1066

  Zachwieja, Jacek ^a   Silska, Magdalena ^a   Ostalska Nowicka, Danuta ^a   Soltysiak, Jolanta ^a   Lipkowska, Katarzyna ^a   Blumczynski, Andrzej ^a   Musielak, Anna ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Children; Nephrotic syndrome; Rituximab

Indexed keywords

CD19 ANTIGEN; COTRIMOXAZOLE; CYCLOSPORIN A; RITUXIMAB;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADOLESCENT; ARTICLE; BODY TEMPERATURE; CHILD; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONGENITAL NEPHROTIC SYNDROME; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TREATMENT FAILURE; FEMALE; FLU LIKE SYNDROME; GLOMERULONEPHRITIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; LYMPHOCYTE COUNT; MALE; NAUSEA; NEPHROTIC SYNDROME; PATIENT MONITORING; PRIMARY GLOMERULONEPHRITIS; PROLIFERATIVE GLOMERULONEPHRITIS; PROTEINURIA; REMISSION; SCHOOL CHILD; SIDE EFFECT; SINGLE DRUG DOSE; STEROID DEPENDENT NEPHROTIC SYNDROME; TREATMENT INDICATION; TREATMENT OUTCOME;

ADOLESCENT; AGE FACTORS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD19; BIOLOGICAL MARKERS; CHILD; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; DRUG MONITORING; FEMALE; GLOMERULONEPHRITIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, INTRAVENOUS; LYMPHOCYTE COUNT; LYMPHOCYTES; MALE; NEPHROTIC SYNDROME; PROTEINURIA; REMISSION INDUCTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 84870576713     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/jn.5000096     Document Type: Article

References (26)

1. Swartz SJ, Eldin KW, Hicks MJ, Feig DI. Minimal change disease with IgM+ immunofluorescence: a subtype of nephrotic syndrome. Pediatr Nephrol. 2009;24(6):1187-1192.
2. Hallan SI, Ritz E, Lydersen S, Romundstad S, Kvenild K, Orth SR. Combining GFR and albuminuria to classify CKD improves prediction of ESRD. J Am Soc Nephrol. 2009;20(5): 1069-1077.
3. D'Cruz DP, Khamashta MA, Hughes GR. Systemic lupus erythematosus. Lancet. 2007;369(9561):587-596.
4. Mishra OP, Thakur N, Mishra RN, Prasad R. Prolonged versus standard prednisolone therapy for initial episode of idiopathic nephritic syndrome. J Nephrol. 2011 Sept 7 [Epub ahead of print].
5. Ehrich JH, Pape L, Schiffer M. Corticosteroid-resistant nephrotic syndrome with focal and segmental glomerulosclerosis: an update of treatment options for children. Paediatr Drugs. 2008;10(1):9-22.
6. Sümegi V, Haszon I, Bereczki C, Papp F, Túri S. Long-term follow-up after cyclophosphamide and cyclosporine-A therapy in steroid-dependent and -resistant nephrotic syndrome. Pediatr Nephrol. 2008;23(7):1085-1092.
7. Vécsei AK, Müller T, Schratzberger EC, et al. Plasmapheresis-induced remission in otherwise therapy-resistant FSGS. Pediatr Nephrol. 2001;16(11):898-900.
8. Gargah TT, Lakhoua MR. Mycophenolate mofetil in treatment of childhood steroid-resistant nephrotic syndrome. J Nephrol. 2011;24(2):203-207.
9. Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol. 2002;29(1)(Suppl 2):2-9.
10. Haffner D, Fischer DC. Nephrotic syndrome and rituximab: facts and perspectives. Pediatr Nephrol. 2009;24(8): 1433-1438.
11. Dudzik B, Kaczmarczyk I, Radziszewski A, Sułowicz W. Use of cyclosporine A and new immunosuppressive drugs in the therapy of glomerulonephritis. Przegl Lek. 2001;58(7-8):798-804.
12. Fikes BJ. Why San Diego has biotech. San Diego Metropolitan. April 1999. Available at: http://www.biogenidec.com/history.html. Accessed June 20, 2008.
13. Herold M, Haas A, Srock S, et al; East German Study Group Hematology and Oncology Study. Rituximab added to firstline mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol. 2007;25(15):1986-1992.
14. Edwards JCW, Szczepáski L, Szechiń ski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350(25):2572-2581.
15. Grimbert P, Audard V, Remy P, Lang P, Sahali D. Recent approaches to the pathogenesis of minimal-change nephrotic syndrome. Nephrol Dial Transplant. 2003;18(2):245-248.
16. Salama AD, Pusey CD. Drug insight: rituximab in renal disease and transplantation. Nat Clin Pract Nephrol. 2006;2(4): 221-230.
17. Smith GC. Is there a role for rituximab in the treatment of idiopathic childhood nephrotic syndrome? Pediatr Nephrol. 2007;22(6):893-898.
18. Westphal S, Hansson S, Mjörnstedt L, Mölne J, Swerkersson S, Friman S. Early recurrence of nephrotic syndrome (immunoglobulin m nephropathy) after renal transplantation successfully treated with combinations of plasma exchanges, immunoglobulin, and rituximab. Transplant Proc. 2006;38(8):2659-2660.
19. Bagga A, Sinha A, Moudgil A. Rituximab in patients with the steroid-resistant nephrotic syndrome. N Engl J Med. 2007;356 (26):2751-2752.
20. Nakayama M, Kamei K, Nozu K, et al. Rituximab for refractory focal segmental glomerulosclerosis. Pediatr Nephrol. 2008;23(3):481-485.
21. Alchi B, Jayne D. Membranoproliferative glomerulonephritis. Pediatr Nephrol. 2010;25(8):1409-1418.
22. Sfikakis PP, Boletis JN, Tsokos GC. Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future. Curr Opin Rheumatol. 2005;17(5):550-557.
23. Anolik JH, Campbell D, Felgar RE, et al. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum. 2003;48(2):455-459.
24. Filler G, Huang SH, Sharma AP. Should we consider MMF therapy after rituximab for nephritic syndrome? Pediatr Nephrol. 2011;26(10):1759-1762.
25. Nwobi O, Abitbol CL, Chandar J, Seeherunvong W, Zilleruelo G. Rituximab therapy for juvenile-onset systemic lupus erythematosus. Pediatr Nephrol. 2008;23(3):413-419.
26. Calabrese LH, Molloy ES, Huang D, Ransohoff RM. Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease. Arthritis Rheum. 2007;56(7):2116-2128.